These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25215436)

  • 1. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
    Sharkovska Y; Reichetzeder C; Alter M; Tsuprykov O; Bachmann S; Secher T; Klein T; Hocher B
    J Hypertens; 2014 Nov; 32(11):2211-23; discussion 2223. PubMed ID: 25215436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
    Spencer NY; Yang Z; Sullivan JC; Klein T; Stanton RC
    PLoS One; 2018; 13(7):e0200249. PubMed ID: 29979777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
    Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease.
    Al Tuhaifi T; Zhong J; Yang HC; Fogo AB
    Lab Invest; 2024 Feb; 104(2):100305. PubMed ID: 38109999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
    Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
    Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K
    Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.
    Cooper ME; Perkovic V; Groop PH; Hocher B; Hehnke U; Meinicke T; Koitka-Weber A; van der Walt S; von Eynatten M
    J Hypertens; 2019 Jun; 37(6):1294-1300. PubMed ID: 30540657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
    Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T; Oka K; Ueda H; Imai E
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
    Jung E; Kim J; Ho Kim S; Kim S; Cho MH
    Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MARLINA-T2D trial: putting the results into clinical perspective.
    Lajara R
    Expert Rev Endocrinol Metab; 2018 May; 13(3):173-176. PubMed ID: 30058901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.
    Sedeek M; Gutsol A; Montezano AC; Burger D; Nguyen Dinh Cat A; Kennedy CR; Burns KD; Cooper ME; Jandeleit-Dahm K; Page P; Szyndralewiez C; Heitz F; Hebert RL; Touyz RM
    Clin Sci (Lond); 2013 Feb; 124(3):191-202. PubMed ID: 22920224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
    Ma M; Hasegawa Y; Koibuchi N; Toyama K; Uekawa K; Nakagawa T; Lin B; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2015 May; 14():54. PubMed ID: 25986579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
    Abouelkheir M; El-Metwally TH
    Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment.
    Mikov M; Pavlović N; Stanimirov B; Đanić M; Goločorbin-Kon S; Stankov K; Al-Salami H
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):1-14. PubMed ID: 31385198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.